Comparative Pharmacology
Head-to-head clinical analysis: FASENRA versus KESIMPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASENRA versus KESIMPTA.
FASENRA vs KESIMPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
KESIMPTA (ofatumumab) is a fully human anti-CD20 monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, leading to B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This results in depletion of circulating B cells, reducing inflammatory demyelination in multiple sclerosis.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
20 mg administered subcutaneously once monthly after a loading dose of 20 mg on Days 0, 7, and 14.
None Documented
None Documented
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
16 days (range 13–20 days) with linear pharmacokinetics; supports every 4-week dosing.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Primarily degraded into small peptides and amino acids; not excreted renally or fecally as intact drug. Elimination pathways not fully characterized due to monoclonal antibody catabolism.
Category C
Category C
Monoclonal Antibody, Anti-Interleukin-5 Receptor
Monoclonal Antibody, Anti-CD20